Filed with ASX · · 35 pages · English
Dimerix Limited has released a presentation for the Canaccord Drug and Device Conference and investor meetings in Hong Kong, highlighting its clinical programs for kidney diseases. Dimerix is focused on developing therapies for conditions with significant unmet medical needs, particularly in kidney diseases. The company aims to engage with investors and demonstrate its advancements in clinical development during these events.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
For Immediate Release DIMERIX PRESENTATION FOR CANACCORD DRUG AND DEVICE 2026 CONFERENCE AND HONG KONG MEETINGS MELBOURNE, Australia, 12 October 2026: Dimerix Limited (ASX: DXB, “Dimerix”), a clinical-stage biopharmaceutical company developing treatments for kidney disease, is pleased to...
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix